EQ

EMBARQ CORPORATION
EQ

Overview Fund Activity
Delisted

EQ was delisted on the 30th of June, 2009.

Back to rankings
Communication Services Telecom Services

Financial journalist opinion

Neutral
Business Wire
9 days ago
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
The Motley Fool
10 days ago
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
Neutral
Business Wire
14 days ago
Equillium to Participate in the Cantor Global Healthcare Conference 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.
Equillium to Participate in the Cantor Global Healthcare Conference 2025
Positive
Seeking Alpha
15 days ago
Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC
Equillium, Inc. secured up to $50 million in funding to advance EQ504, its novel AhR modulator, for ulcerative colitis treatment. A phase 1 proof-of-concept study for EQ504 in ulcerative colitis is set to begin in mid-2026, with early data expected within six months afterwards. EQ504's mechanism is validated by Tapinarof's approval in skin disorders, supporting its potential in both gastrointestinal and lung indications; Along with POC of anti-inflammatory cytokines IL-10 and IL-22.
Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC
Neutral
Business Wire
1 month ago
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross proce.
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
Neutral
Business Wire
1 month ago
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. “As we are actively evaluating strategic options for the company, I am pleased to announce we have expanded our treasury strategy to include digital currencies for the diversif.
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
Neutral
Business Wire
4 months ago
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7. “Decades of independent research have validated Ah.
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
Neutral
Business Wire
4 months ago
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of Ariagen, a biotechnology company that was majority owned by Equillium's largest investor, Decheng Capital. AhR.
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
Neutral
Business Wire
4 months ago
Equillium Announces Feedback from the U.S. Food and Drug Administration
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for Accelerated Approval, as well as the company's filing for Breakthrough Therapy designation for.
Equillium Announces Feedback from the U.S. Food and Drug Administration
Positive
Zacks Investment Research
5 months ago
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
See News Rankings
Charts implemented using Lightweight Charts™